We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

69 hedge funds and large institutions have $87.7M invested in Gyre Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,200% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $43K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.93% less ownership

Funds ownership: 9.54% → 8.61% (-0.93%)

22% less capital invested

Capital invested by funds: $113M → $87.7M (-$25.2M)

22% less funds holding

Funds holding: 89 → 69 (-20)

38% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 29

67% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 30

Holders
69
Holders Change
-20
Holders Change %
-22.47%
% of All Funds
1.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
18
Reduced
29
Closed
30
Calls
$1.85M
Puts
$43K
Net Calls
+$1.81M
Net Calls Change
-$539K

Top Buyers

1
2L
22NW LP
Washington
+$2.99M
2
SCM
Stonepine Capital Management
Oregon
+$2.87M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.05M
4
Millennium Management
Millennium Management
New York
+$1.14M
5
RC
RBF Capital
California
+$724K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.3M
2
BlackRock
BlackRock
New York
-$6.26M
3
State Street
State Street
Massachusetts
-$1.53M
4
ACP
Acuta Capital Partners
California
-$1.16M
5
Northern Trust
Northern Trust
Illinois
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$463K -$1.05M -30,572 -68%
Morgan Stanley
27
Morgan Stanley
New York
$458K +$212K +6,177 +77%
SSA
28
Schonfeld Strategic Advisors
New York
$411K +$43K +1,253 +11%
HF
29
HRT Financial
New York
$388K +$411K +11,973 New
MHS
30
M Holdings Securities
Oregon
$369K -$41.2K -1,200 -10%
JP Morgan Chase
31
JP Morgan Chase
New York
$368K -$192K -5,596 -33%
TEE
32
Tibra Equities Europe
United Kingdom
$343K +$362K +10,560 New
EWM
33
Essex Woodlands Management
Texas
$340K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$326K -$280K -8,153 -45%
DC
35
Davenport & Co
Virginia
$301K +$31.1K +906 +11%
JJIJ
36
Johnson & Johnson Innovation - JJDC
New Jersey
$290K – – –
BFM
37
Boothbay Fund Management
New York
$288K -$9.13K -266 -3%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$239K +$92.4K +2,692 +58%
TAM
39
Tocqueville Asset Management
New York
$236K +$68.6K +2,000 +38%
RJFSA
40
Raymond James Financial Services Advisors
Florida
$217K -$236K -6,866 -51%
Squarepoint
41
Squarepoint
New York
$204K -$104K -3,031 -33%
State Street
42
State Street
Massachusetts
$188K -$1.53M -44,644 -89%
BDF
43
Black Diamond Financial
Maryland
$182K +$18.3K +533 +11%
Two Sigma Investments
44
Two Sigma Investments
New York
$166K -$807K -23,508 -82%
Barclays
45
Barclays
United Kingdom
$145K -$102K -2,961 -40%
HSBC Holdings
46
HSBC Holdings
United Kingdom
$141K +$23.3K +678 +19%
TI
47
Trexquant Investment
Connecticut
$140K +$147K +4,296 New
Bank of America
48
Bank of America
North Carolina
$134K -$135K -3,948 -49%
PPA
49
Parametric Portfolio Associates
Washington
$91K -$104K -3,028 -52%
ASN
50
Advisory Services Network
Georgia
$85K +$90.2K +2,627 New
1
2
3 4

GYRE Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2021, worth a combined $87.7M — down 22% from $113M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of GYRE and 10 opened new positions — a net loss of 20 holders — while 29 trimmed existing stakes and 18 added.

The largest buyer was 22NW LP, adding an estimated $2.99M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.3M sold.

  • 69 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2021, down from 89 in Q1 2021.
  • Funds reported $87.7M of Gyre Therapeutics stock for Q2 2021, down 22% quarter-over-quarter.
  • 10 funds opened new Gyre Therapeutics positions in Q2 2021 and 30 closed out, a net change of -20 holders.
  • The largest Gyre Therapeutics buyer in Q2 2021 was 22NW LP, an estimated $2.99M added.
  • The largest Gyre Therapeutics seller in Q2 2021 was Opaleye Management, an estimated $6.3M sold.

Based on aggregated 13F filings for Q2 2021.